Moreover, cells HER-2 overexpressing (UNESP-CM1, UNESP-CM60 and UNESP-MM4) had the higher doses to achieve IC50 than triple negative non-basal tumor cells (UNESP-MM1), which indicated that rapamycin could have a better response on triple negative cells when compared to HER-2 overexpressing cells. The gene discussed is ERBB2; the disease is neoplasm.